AFP and hepatocellular carcinoma: successfully demonstrated the antitumoral effects in preclinical HCC models by engineering AFP-CAR T cells capable of recognizing the AFP peptide presented by MHC class I molecules (59), a subsequent phase I trial (NCT03349255) with the AFP-CAR T cells was terminated (60).